An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.
This accomplishment, described in the Dec. 13, 2012 issue of the journal Nature, may prove invaluable for developing drugs to treat many common human diseases such as diabetes, high blood pressure, obesity, cancer, schizophrenia, and bi-polar disorder.
These disorders are called complex diseases because each have a number of genetic and non-genetic influences that determine susceptibility, i.e., whether someone will get the disease or not.
"In terms of the genetics of schizophrenia we know there are likely hundreds of different genes that can influence the risk for disease and, because of that, there's likely no single gene and no one drug target that will be useful for treating it, like other common complex diseases," said study co-leader, Brian L. Roth, MD, PhD, Michael J. Hooker Distinguished Professor of Pharmacology in the UNC School of Medicine, professor in the Division of Chemical Biology and Medicinal Chemistry in the UNC Eshelman School of Pharmacy, and director of the National Institute of Mental Health Psychoactive Drug Screening Program.
In complex neuropsychiatric conditions, infectious diseases and cancer, Roth points out that for the past 20 years drug design has been selectively aimed at a single molecular target, but because these are complex diseases, the drugs are often ineffective and thus many never reach the market.
Moreover, a drug that acts on a single targeted protein may interact with many other proteins. These undesired interactions frequently cause toxicity and adverse effects.
"And so the realization has been that perhaps one way forward is to make drugs that hit collections of drug targets simultaneously. This paper provides a way to do that," Roth said.
The new way involves automated drug design by computer that takes advantage of large databases of drug-target interactions. The latter have been made public through Roth's lab at UNC and through other resources.
Basically, the researchers, also co-led by Andrew L. Hopkins, PhD in the Division of Biological Chemistry and Drug Discovery, College of Life Sciences, at the University of Dundee, in Scotland, used the power of computational chemistry to design drug compounds that were then synthesized by chemists, tested in experimental assays and validated in mouse models of human disease.
The study team experimentally tested 800 drug-target predictions of the computationally designed compounds; of these, 75 percent were confirmed in test-tube (in vitro) experiments.
Drug to target engagement also was confirmed in animal models of human disease. In a mouse model of attention deficit hyperactivity disorder (ADHD), mice missing a particular dopamine receptor engage in recurrent aberrant behaviors similar to what is seen in ADHD: distractibility and novelty seeking. "We created a compound that was predicted to prevent those recurrent behaviors and it worked quite well," Roth said.
The researchers then tested the compound in another mouse model where a particular enzyme for a brain neuropeptide is missing. Distractibility and novelty seeking also are behavioral features in these animals. And the drug had the same effect in those mice.
The new drug design process includes ensuring that compounds enter the brain by crossing the blood-brain barrier. These, too, were tested successfully in live animals.
According to Roth, pharmaceutical company chemists had suggested that the objective of a drug hitting multiple targets simultaneously is impossible and unlikely to succeed. "Here we show how to efficiently and effectively make designer drugs that can do that."
University of North Carolina Health Care: http://www.med.unc.edu
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Swallowing a sulfur-rich protoplanet could help explain two lingering mysteries in the story of Earth's formation
In a first-of-its-kind endeavor, electricity-starved Rwanda and the Democratic Republic of Congo are trying to get power from a lake—and avert catastrophe.It’s a Friday afternoon on the Rwandan side of Lake Kivu, and in what was once a quiet cove, a daring venture is taking shape.
The good news is that an eruption there is highly unlikely, but the bad news is that it would be huge
Flame-retardant fabrics normally degrade when washed, but a water-repelling coating could make your flame-proof suit or sofa self-cleaning
It may look like nothing more than a small ball of metal, but the shape-shifting and self-propulsion abilities of a liquid metal alloy discovered by scientists at China's Tsinghua University has captured the imaginations of scientists and science-fiction fans across the world.
The same receptor on nerve endings that makes sinuses tingle when we eat wasabi plays an important role in the pain of inflammation. The first 3-D view of the receptor could lead to better pain drugs.
As the craft beer industry grows, so are options for learning to brew. More colleges are now introducing degree programs to teach the art and science of beer-making.
Researchers were surprised by what they found when they sandwiched a drop of water between two layers of an unusual two-dimensional material called graphene.
Scientists at Cern are suggesting they could soon detect miniature black holes, proving the existence of parallel universes and disproving the big bang theory of the creation of the universe.
The Curiosity rover makes a detection of nitrogen compounds which provide further evidence that ancient Mars would have been a habitable world.